• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CEO Bersani Pietro bought $19,530 worth of shares (6,000 units at $3.25), increasing direct ownership by 5% to 138,845 units (SEC Form 4)

    6/12/24 4:35:20 PM ET
    $KRBP
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $KRBP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BERSANI PIETRO

    (Last) (First) (Middle)
    C/O KIROMIC BIOPHARMA INC.
    7707 FANNIN, SUITE 200

    (Street)
    HOUSTON TX 77054

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Kiromic Biopharma, Inc. [ KRBP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    06/11/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/11/2024 P 3,000 A $3.23 135,845 D
    Common Stock 06/12/2024 P 3,000 A $3.28 138,845 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Pietro Bersani 06/12/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KRBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRBP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KRBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bersani Pietro bought $7,407 worth of shares (3,488 units at $2.12), increasing direct ownership by 3% to 142,333 units (SEC Form 4)

      4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)

      8/26/24 6:44:11 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Hungerford Brian bought $8,802 worth of shares (4,000 units at $2.20), increasing direct ownership by 7% to 64,933 units (SEC Form 4)

      4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)

      8/21/24 4:29:54 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Hungerford Brian bought $3,500 worth of shares (2,000 units at $1.75), increasing direct ownership by 3% to 60,933 units (SEC Form 4)

      4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)

      8/14/24 5:03:04 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care

    $KRBP
    Financials

    Live finance-specific insights

    See more
    • Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

      Recent Corporate Highlights Include: New Leadership Appointed at the Company, Board of Director Level Completed Studies to Further Optimize Potency and Validity of the ALEXIS Gamma Delta T (GDT) Cell Platform Progressed a Master Cell Bank Strategy for Retro-viral Vector (RVV) Production Enhanced Kiromic's Diamond AI™ Mediated Pooled Donor Gamma Delta T Cell Banking Technology Expansion and Redesign of In-house cGMP Manufacturing Facility DIAMOND®AI 2.0 New Component NOEMI (NeurO Evolutive) Machine Learning Enabled Antibody Design) Designed to Dramatically Reduce Time and Cost of CAR-T Cell Therapy Development Cash Position $15,123,100 as of March 31, 2022 Kiromic BioPh

      5/13/22 8:08:00 AM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights

      Highlights Include Company's Progress in the Following Areas: Advances in the Research, Development, and Manufacturing Processes of the ALEXIS Gamma Delta T cell Platform Key Hires in Research & Development, Clinical Translational Medicine and Clinical Trial Preparation Completion of Approximately 90% of In-house cGMP Facility Expansion and Redesign Launch of DIAMOND® Artificial Intelligence (AI) 2.0 Platform for Identification and Selection of Immunotherapy Targets, which Now Includes Nearly Two Billion Data Points Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artific

      4/8/22 4:07:00 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid Tumors

      Kiromic Biopharma, Inc. (NASDAQ:KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005822/en/http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview (Graphic: Business Wire)">SpliceSeq, http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview (Graphic: Business Wire) InSilico Solutions is a world-class bio-informatics and artificial intelligence innovator with a long standing collaborative relationship with its clients at MD Anderson Cancer Center, Johns Hopkins School of

      7/26/21 6:55:00 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care

    $KRBP
    SEC Filings

    See more
    • Kiromic BioPharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

      8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)

      3/21/25 9:05:01 AM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kiromic BioPharma Inc. filed SEC Form 8-K: Other Events

      8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)

      3/17/25 5:26:56 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form S-1/A filed by Kiromic BioPharma Inc.

      S-1/A - Kiromic Biopharma, Inc. (0001792581) (Filer)

      2/19/25 4:57:39 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care

    $KRBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kiromic BioPharma Inc.

      SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)

      11/4/24 7:38:30 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Kiromic BioPharma Inc.

      SC 13D - Kiromic Biopharma, Inc. (0001792581) (Subject)

      5/20/24 5:00:06 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Kiromic BioPharma Inc. (Amendment)

      SC 13D/A - Kiromic Biopharma, Inc. (0001792581) (Subject)

      5/9/24 5:00:18 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care

    $KRBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival

      Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports continued favorable efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial and provides an enrollment update. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic or locally-advanced non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. The fourth patient in Deltacel-01 demonstrated a partial response (defined as a 30% or greater decrease in the size of the tumor) at the eight-month follow-up visit and continued w

      2/18/25 8:00:00 AM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01

      Provides Enrollment Update for Phase 1 Study in Late-Stage Non-small Cell Lung Cancer Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable efficacy results from the 12-month follow-up visit for the first patient and the two-month follow-up visit for the seventh patient enrolled in its Deltacel-01 Phase 1 clinical trial, and provides an enrollment update. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic or locally-advanced non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. At the 12-month post-treatment follow-up vi

      1/21/25 8:00:00 AM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01

      Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from the eight-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial, and provides additional updates on the first and seventh patients. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. 8-Month Follow-Up for Patient #4: Partial Response with Tumor Reduction of 32% Preliminary results from the eight-month follow-up visit for the fourth patient enro

      12/12/24 8:00:00 AM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care

    $KRBP
    Leadership Updates

    Live Leadership Updates

    See more
    • Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer

      Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company's Vice President of Research & Development and Clinical Translation since September 2021. His previous role was Head of Clinical Translation from 2020 to 2021, having joined the Company in 2016 as Executive Director of Research and Development (R&D). "We are delighted to name

      7/12/22 8:18:00 AM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company's Board of Directors

      – Frank Tirelli Will Serve as Chair of Kiromic's Audit Committee – – Dr. Reeves Brings Deep Biopharmaceutical, Regulatory, and Clinical Expertise to Board Role – Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces the appointment of two outside directors to the Company's Board of Directors: Frank Tirelli and Karen Reeves, M.D. Frank Tirelli was appointed to the Company's Board effective on January 28,

      2/3/22 8:02:00 AM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing Officer

      HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP) — Expansion of in-house cGMP manufacturing facility to provide support to the Company's clinical trials. Therapeutic doses expected to be ready for first in-human dosing in 3Q-2021. — Mr. Ignacio Núñez, a 20-year industry veteran in global operations and manufacturing, is joining the Kiromic team to take the company to the next level and to scale up cGMP manufacturing capabilities internally. Kiromic is an immuno-oncology company using Artificial Intelligence (AI) to identify critical markers in solid tumors to develop Allogeneic CAR-T cell therapy. Kiromic’s CAR-T technology addresses critical efficacy and safet

      6/7/21 8:07:00 AM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care

    $KRBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bersani Pietro bought $7,407 worth of shares (3,488 units at $2.12), increasing direct ownership by 3% to 142,333 units (SEC Form 4)

      4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)

      8/26/24 6:44:11 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Hungerford Brian bought $8,802 worth of shares (4,000 units at $2.20), increasing direct ownership by 7% to 64,933 units (SEC Form 4)

      4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)

      8/21/24 4:29:54 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Hungerford Brian bought $3,500 worth of shares (2,000 units at $1.75), increasing direct ownership by 3% to 60,933 units (SEC Form 4)

      4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)

      8/14/24 5:03:04 PM ET
      $KRBP
      Medicinal Chemicals and Botanical Products
      Health Care